Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) continued to trade lower on Wednesday as Wolfe Research downgraded the cystic ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its ...

Shares of Vertex Pharmaceuticals Inc. plunged 10.03% to $450.03 Tuesday, on what proved to be an all-around grim trading ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Neurocrine Biosciences, Inc. today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial ...

Vertex Pharmaceuticals is prepping for its Q1 earnings reveal on May 5, with analysts expecting mixed results. EPS is ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 2.09% to $498.86 Thursday, on what proved to be an all-around great trading ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...